MedTrace Logo

Symbiot III: A Prospective Randomized Trial Evaluating the Symbiot Covered Stent System in Saphenous Vein Grafts

NCT00283413 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 514

Last updated 2009-11-02

No results posted yet for this study

Summary

The objective of the Symbiot III Clinical Trial was to evaluate the safety and effectiveness of the Symbiot Covered Stent System in the treatment of symptomatic ischemic saphenous vein bypass graft disease.

Conditions

  • Symptomatic Ischemic Saphenous Vein Graft Disease

Interventions

DEVICE

Covered Stent System

Self-expanding, polytetrafluoroethylene(PTFE)-covered, stent system

DEVICE

Bare metal stent

Any commercially available bare metal stent for coronary indication

Sponsors & Collaborators

  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Mark Turco, MD · Washington Adventist Hospital, Takoma Park, MD

  • Maurice Buchbinder, MD · Foundation for Cardiovascular Medicine, La Jolla, CA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-03-31
Primary Completion
2004-05-31
Completion
2009-03-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00283413 on ClinicalTrials.gov